Role of gut microbiota and mesenteric adipose tissue in the pathology of Crohn’s disease:Potential therapeutic targets  

在线阅读下载全文

作  者:Han-Jung Liu Meng-Che Wu Shuo-Yan Gau 

机构地区:[1]School of Medicine,Chung Shan Medical University,Taichung 402,Taiwan [2]Division of Pediatric Gastroenterology,Children's Medical Center,Taichung Veterans General Hospital,Taichung 40705,Taiwan [3]Department of Post-Baccalaureate Medicine,College of Medicine,National Chung Hsing University,Taichung 402202,Taiwan [4]Department and Graduate Institute of Business Administration,National Taiwan University,Taipei 106319,Taiwan

出  处:《World Journal of Gastroenterology》2025年第13期1-6,共6页世界胃肠病学杂志(英文)

摘  要:This editorial comments on the article by Wu et al in the World Journal of Gastroenterology.The article explored the relationship between mesenteric adipose tissue,creeping fat,inflammation,and gut microbiota in Crohn’s disease(CD).We discussed three key aspects of the interaction between gut microbiota and inflammatory bowel disease(IBD):The physiological functions of the gut microbiota,the potential role of probiotics in IBD treatment;and the effect of fecal microbiota transplantation(FMT)in combating IBD.IBD,comprising CD and ulcerative colitis(UC),is influenced by the gut microbiota.Changes in gut microbiota composition disrupt intestinal function and promote chronic inflammation,but the exact mechanisms remain unclear.Probiotics have demonstrated some efficacy in inducing remission in UC,though their effectiveness in CD is still debated.FMT shows promise in treating IBD,especially UC,by restoring gut microbiota diversity and inducing clinical remission.As for CD,FMT has potential,but more studies are needed to confirm its long-term effectiveness and safety.Dietary approaches may help manage IBD symptoms or disease activity,but patient adherence is crucial.Clinicians and researchers must recognize the importance of the gut microbiota and the need for personalized therapies targeting microbial imbalances.

关 键 词:Crohn’s disease Gut microbiota PROBIOTICS Ulcerative colitis Inflammatory bowel disease 

分 类 号:R57[医药卫生—消化系统]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象